Back to results
US 2023/0346797 A1Published application
Inhibitors of the plasmodial surface anion channel as antimalarials
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsSanjay A. Desai, Ajay D. Pillai
Life of this patent
Estimating the term…
Abstract
Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.
Claims10
-99. (canceled)
A pharmaceutical composition comprising a pharmaceutically acceptable carrier,
- (i) a compound of formula IV:
- wherein
- Z is a group having one or more 4-7 membered rings, wherein at least one of the rings has at least one heteroatom selected from the group consisting of O, S, and N;
- and when two or more 4-7 membered rings are present, the rings may be fused or unfused;
- wherein the rings are optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, alkoxy, nitro, cyano, amino, alkyl, aminoalkyl, alkylamino, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, and formyl;
- Ra is hydrogen, alkyl, or alkoxy;
- P is a bond, alkyl, alkoxy, (CH2)r, or (CH2O)s, wherein r and s are independently 1 to 6;
- Q is a heterocyclic group, an aryl group, or an heterocyclyl aryl group, each of which is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, alkoxy, nitro, cyano, amino, alkyl, aminoalkyl, alkylamino, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, and formyl;
- and
- when P is alkyl or alkoxy, Q is absent;
- or a pharmaceutically acceptable salt thereof;
- and
- (ii) a compound of formula V:
- wherein R11 and R12 are independently hydrogen, alkyl, cycloalkyl, or aryl which is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halo, hydroxy, nitro, cyano, amino, alkylamino, aminoalkyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, and formyl;
- R13-R15 are independently selected from the group consisting of alkyl, halo, alkoxy, hydroxy, nitro, cyano, amino, alkylamino, aminoalkyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, and formyl;
- or a pharmaceutically acceptable salt thereof.
13 more elements
Dependencies are inferred from the claim text.